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An update on the management of acne vulgaris
Abstract: Acne vulgaris is a common skin disorder that can affect individuals from childhood 
to adulthood, most often occurring in the teenage years. Acne can have a significant physical, 
emotional, and social impact on an individual. Many different treatment options are available 
for the treatment of acne vulgaris. Commonly used topical treatments include benzoyl peroxide, 
antibiotics, sulfur and sodium sulfacetamide, azelaic acid, and retinoids. Systemic treatment 
is frequently used and includes the use of systemic antibiotics, oral contraceptives, antiandro-
gens, and retinoids. Other treatment modalities exist such as the use of superficial chemical 
peels as well as using laser and light devices for the treatment of acne. With the multitude of 
treatment options and the rapidly expanding newer technologies available to clinicians, it is 
important to review and be aware of the current literature and studies regarding the treatment 
of acne vulgaris.
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Introduction
Acne is a common skin disorder affecting most individuals in the teenage years but 
also affecting anyone from childhood to middle age. The treatment for acne dates back 
to Egyptian times when sulfur was used, to recent times with new forms of treatment 
with lasers and lights. Why treat acne? Many in the lay community feel that acne is 
a rite of passage into adulthood and needs no treatment. However, dermatologists 
can vouch for the physical and emotional scars of acne when left untreated. The 
psychosocial implications can be huge with serious implications regarding the effect 
on self-image and the quality of life, so that the impact of acne may be equivalent to 
that of asthma or epilepsy.1 This review will concentrate on prescription-based treat-
ments. A good review of over-the-counter acne treatments can be found in a recent 
review of these products.2
Benzoyl peroxide
Benzoyl peroxide (BP) has long been the mainstay of treatment for acne. It is available 
in a variety of over-the-counter and prescription formulations. These formulations 
may include a number of ingredients that differentiate one product from another. For 
example, BP may be combined with glycolic acid, urea, or placed into microspheres 
for a more gentle delivery. It may be used as a wash or leave-on product that may 
be formulated as a gel or cream. BP washes are easy to use and show efficacy in the 
30% to 40% range. Such washes are good for truncal acne, as the medication can be 
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dispersed by water while having a shower. Its comedolytic 
and antibacterial properties are quite useful in the treatment 
of acne. Antibacterial resistance does not appear to occur 
with BP, and BP combinations are well documented in 
decreasing the number of resistant organisms to commonly 
used antiacne antibiotics by effectively destroying micro-
organisms before resistance can develop.3 When giving 
long-term oral antibiotics, BP is an important adjuvant drug 
to employ, as it reduces the number of antibiotic resistant 
organisms. Concerns in the use of BP include irritation 
and contact sensitivity. It also has a bleaching property, so 
that when it is not removed completely, it can often bleach 
clothing and bedding.4 In addition, it can bleach the skin of 
darker individuals and this must be discussed while initiat-
ing therapy in the ethnic population. Recently, combination 
products have been highly successful in the treatment of 
acne. Patients have enjoyed the ease of applying only one 
product that can deliver both BP and the topical antibiotics, 
erythromycin and clindamycin. In the future, BP may be 
compounded with other agents as well. In many cases, acne 
treatment requires a combination therapy, as monotherapy 
is often less successful.5
Topical antibiotics
In addition to the combination products described above, 
topical antibiotics alone can be useful in the treatment of 
acne. Clindamycin and erythromycin work by inhibiting 
Propionibacterium acnes at the 50S ribosomal subunit where 
they bind irreversibly to inhibit protein synthesis. P. acnes 
can thrive in an environment that combines sebum and 
desquamated cells, where it converts sebum to free fatty acids, 
which then stimulate the body’s immune response. Topical 
antibiotics act against this organism, in addition to having 
anti-inflammatory properties, making these medications use-
ful in the treatment of acne.6 Alone, these medications come 
in the form of solutions, pledgets, lotions, gels, ointments, 
and foams. They can be used in such combination products 
but can also be used in conjunction with BP washes, when 
leave-on BP is too irritating. Choosing the formulation of 
the antibiotic is dependent on the patients’ lifestyle and skin 
type. Gels are better suited for oily skin, whereas, lotions and 
ointments work better on drier skin. For truncal use, foams 
and specific delivery systems using long armed applicators, 
such as ClindaReach® (DUSA Pharmaceuticals, Wilmington, 
MA, USA) offer the advantage of application to difficult-
to-reach areas of the body. Topical antibiotics, when mixed 
with BP and systemic agents, make a good combination in 
treating acne.
Understanding the cost and efficacy of different treatment 
options is important in deciding which one to choose. A rand-
omized controlled trial studying the cost and efficacy of using 
BP and topical erythromycin in different regimen combina-
tions concluded that BP as an exclusive treatment option 
was the most cost-effective option, yet caused more local 
irritation. In combination with erythromycin, there was less 
irritation. There was little difference whether erythromycin 
and benzoyl peroxide were administered separately or as a 
combined formulation, in terms of efficacy and irritation; 
however, the drugs applied seperately were three times more 
cost-effective.7
Topical sulfur and sodium 
sulfacetamide
Sulfur, used for acne since the time of Cleopatra, is useful 
as a drying and antibacterial agent. It is available in washes, 
leave-on lotions, creams, foam formulations, and also as 
prescription and non-prescription masks. Sulfur can be useful 
when treating patients who may also have rosacea and/or 
seborrheic dermatitis, as these conditions can also respond 
to this medication. Sodium sulfacetamide is often combined 
with sulfur and has anti-inflammatory properties. When used 
alone, it can also treat acne and is marketed for the sensitive 
skin acne patient.8
Topical azelaic acid
Azelaic acid is useful in the treatment of acne and the 
post-inflammatory pigment changes that often accompany it. 
Its mechanism of action is by inhibition of protein synthesis, 
although the exact mechanism is unknown. Though patients 
often report a burning or stinging sensation with topical 
application, this usually dissipates in a few (1–4) weeks. 
This medication can be used daily and increased to twice-
daily dosing to allow for some tolerance to build. Azelaic 
acid has shown to be effective in combination with other 
topical agents such as benzoyl peroxide, clindamycin gel, 
erythromycin gel, and tretinoin cream.9
Topical retinoids
The topical retinoids used in the treatment of acne include 
adapalene, tretinoin, and tazarotene. They are comedolytic and 
anti-inflammatory. Different formulations aid in decreasing 
irritation, which is the main side-effect that hinders 
continued use of this class of drugs. Such medications 
have been formulated into microsponge delivery systems 
(Retin-A Micro®; OrthoNeutrogena, Skillman, NJ, USA), 
combined with topical antibiotics and formulated to have Clinical, Cosmetic and Investigational Dermatology 2009:2 107
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a more extended release, made into a stable formulation of 
both solubilized and crystalline tretinoin (Ziana®; Medicis 
Pharmaceutical Corporation Scottsdale AZ, USA), and made 
into cream rather than gel forms (Differin®; Galderma Labo-
ratories, Fort Worth, TX, USA) with the goal of causing less 
irritation on the skin. Of the topical retinoids, adapalene has 
the least irritant effect among the three listed above, though 
it still can cause irritation to the user, even when instructions 
are followed. A recent review of adapalene cited it as a more 
stable molecule than tretinoin and one that can be used with 
BP, as well as during the day because of this stability.10 
Conversely, another review of a large cohort of patients over 
52 weeks found that an aqueous gel formulation of clindamy-
cin (1.2%) and a stable combination of tretinoin, which were 
both crystalline and solubilized, was well tolerated and was 
effective in treating both inflammatory and noninflammatory 
lesions.11 A novel way of getting around the irritant effect 
with tazarotene is the short contact method, where, as little 
as 30 seconds of skin contact resulted in a decrease in acne 
lesions.12 This technique can also be used to increase topical 
contact time in a gradual fashion. In general, retinoids are 
considered to be very important in long-term maintenance 
therapy of acne. Drug companies are looking for ways to 
improve compliance by decreasing the irritation factor of 
topical retinoids. The important feature of the retinoids, treat-
ing not only the visible but also the invisible lesions must 
be stressed to the patient. Patients should be given detailed 
instructions for use, which should include, the amount to be 
used, the duration that the medication would take to produce 
visible changes, as well as potential side-effects.
Finally, regarding retinoids, there is one recent reference 
question on whether the topical form of these medications 
can lead to systemic side-effects. Though this issue comes 
up repeatedly, there is very little evidence. Recently, there 
was a single case report of a 23-year-old woman using 
adapalene 0.1% gel, who developed severe headaches and 
neck stiffness.13 The patient was on no other medications, but 
was found to have swollen optic discs, although she also had 
a normal cerebrospinal fluid pressure on lumbar puncture. Six 
weeks after discontinuation of the adapalene, the discs were 
back to normal and the headaches were gone. The authors 
note that the patient had no other risk factors except for being 
mildly overweight at 70.3 kg at a height of 164.5 cm.
Systemic antibiotics
Oral antibiotics are an important treatment option for 
moderate to severe acne. It was in the 1950s that oral 
tetracycline and erythromycin were used to treat acne. 
Since then, antibiotics used to treat acne have come to include 
doxycycline, minocycline, trimethoprim/sulfamethoxazole, 
amoxicillin, azithromycin, and cephalexin. As with the 
development of novel formulations for topical acne medica-
tions, oral antibiotics have seen some modifications in their 
formulations as well. Antibiotic dosage for acne has generally 
followed treatment regimens as for other conditions treated 
with the same antibiotics. Such doses include, doxycycline 
100 mg twice daily or erythromycin 500 mg twice daily. 
Recently, two novel uses of antibiotics have come to the 
forefront. The first is by prescribing a sub-MIC (minimal 
inhibitory concentration) dose, where the antibiotic acts as 
an anti-inflammatory medication rather than an antibiotic. 
Doxycycline at 20 mg twice daily is considered to be a sub-
MIC dose.14 Another novel dosage/formulation regimen 
involves using a sustained release form of minocycline which 
is prescribed in a weight based manner (1 mg/kg/day) with 
the idea that preventing high levels of the antibiotic in the 
blood, rapidly after ingestion will lead to less side-effects. 
This preparation of sustained release minocycline (Solodyn®; 
Medicis Pharmaceutical Corporation, Scottsdale, AZ, USA) 
has been suggested to have less vestibular side-effects, but 
has yet to show a decrease in other minocycline induced side 
effects. Although most dermatologists prefer the tetracycline 
class of antibiotics when dealing with acne, there is evidence 
that other antibiotics can be helpful. An alternative dosage 
plan with azithromycin 500 mg daily, for four days of the 
month had similar efficacy as doxycycline 100 mg daily.15 
Multiple other studies using azithromycin as an alternate drug 
have also shown some positive results. Moreover, a recent 
study using cephalexin has reported positive results, (49% 
of patients were clear of acne or much improved). Although 
the study design was a retrospective chart review, cephalexin 
may be an inexpensive alternative when other medications 
are not available.16
There are multiple controversies when it comes to treating 
acne patients with long-term antibiotics. These include risk 
of antibacterial resistance and other conditions such as breast 
cancer, as well as serious autoimmune reactions. Regarding 
antibacterial resistance, it is important to explain this concept 
to the patients/caregivers and at the same time employ 
methods to decrease such resistance. This is as simple as 
having patients use a combination product of BP and a topical 
antibiotic, while they are on long-term oral antibiotics. It is 
important to note that there are some risks to systemic anti-
biotics with respect to bacterial resistance. In addition to the 
obvious dermatologic complication of gram-negative acne or 
folliculitis after long-term oral antibiotics, there is also the risk Clinical, Cosmetic and Investigational Dermatology 2009:2 108
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of increased upper respiratory tract infections. Acne patients 
on oral antibiotics are about two times more likely to develop 
an upper respiratory tract infection, though their household 
contacts do not appear to be at an increased risk.17
After a 9-year follow-up of 2.1 million women, the 
observed associations of tetracyclines and macrolides with 
breast cancer were weak and could be explained by other 
diseases or factors.18
Autoimmune reactions to antibiotics used to treat acne 
have been associated most often with minocycline. A review 
of serious adverse reactions to minocycline included autoim-
mune hepatitis, serum sickness and vasculitis, and a lupus-like 
syndrome where the complement remains normal, and these 
serious events appear to be genetically determined by HLA-
type, DR4+, DR2+.19 A more recent review of patients with 
minocycline induced autoimmunity (MIA) looked at a 10-year 
period of patients referred to a tertiary hospital rheumatology 
service for the treatment of MIA.20 This was found to be a very 
rare entity, accounting for 0.05% of all children referred to the 
rheumatology clinic at the tertiary children’s hospital. Most 
autoimmune reactions to minocycline are probably mild and go 
away undiagnosed. However, of the 27 patients in this study, 
7 had persistent chronic autoimmune disease 48 months later, 
requiring such medications as methotrexate, etanercept and 
mycophenolate mofetil. There may be a genetic predisposition 
as it is more common in women, and dermatologists should 
be aware of this. Doxycyline is also known to trigger severe 
autoimmune reactions such as reported in a 20-year-old woman 
on doxycycline for facial acne who presented with fever, 
lymphadenopathy, hepatitis, nephritis, and severe pneumonitis 
with respiratory failure.21
Oral contraceptives  
and antiandrogens
Hormonal manipulation in the treatment of acne came to 
the forefront in the early 1990s. Currently in the United 
States there are three oral contraceptive pills approved by 
the Federal Drug Agency (FDA) for the treatment of acne 
in women. These include ethinyl estradiol and norgestimate 
(Ortho Tri-Cyclen®; Ortho-McNeil-Janssen Pharmaceuticals, 
Titusville, NJ, USA), norethindrone acetate and ethinyl 
estradiol (Estrostep®; Warner-Lambert, Morris Plains, NJ, 
USA) and ethinyl estradiol/drosperinone (YAZ®; Bayer, 
Wayne, NJ, USA). In other countries around the world, 
cyproterone acetate (Diane-35®; Bayer Pty Ltd, Singapore) 
is also used for the treatment of acne. The progestin 
drosperinone, found in products of brands such as YAZ® 
and Yasmin® (Bayer, Wayne, NJ, USA), have about the 
same antiandrogen activity of 25 mg of spironolactone. 
Although hormonal manipulation will help many patients 
with acne, it is imperative that dermatologists also be on 
the lookout for endocrinopathies such as polycystic ovarian 
syndrome (PCOS). PCOS patients often have irregular 
menses, hirsutism, acne, infertility, and obesity. However, 
with this syndrome the patient may not fit the textbook 
description. A recent review of the evaluation of a patient 
with suspected hormonal imbalance and acne provides 
great decision-making algorithms for those treating such 
patients.22 Early identification of such patients can have 
long-term health benefits, as these patients are more likely 
to develop insulin resistance and cardiovascular disease than 
women without PCOS. For patients with PCOS and acne, the 
ethinylestradiol/drosperinone combination pill can help with 
both conditions.23 In addition, this combination pill (YAZ®) 
has been approved for premenstrual dysmorphic disorder 
(PMDD), a psychiatric diagnosis, associated with severe 
symptoms prior to menstruation.
Spironolactone is another option for patients with acne. 
As an antiandrogen, spironolactone has produced good results 
in the PCOS patient, as well as in the patient without PCOS, 
but who has menstrual acne flares and deep cystic acne. 
Spironolactone should not be given to those who have renal 
impairment. Since it can retain potassium, a good review of 
other medications the patient is on, is imperative, to exclude 
potassium retaining medications. Chronic nonsteroidal anti-
inflammatory medications can also increase potassium and 
this should be considered when prescribing spironolactone. 
In addition, this is a category X drug in pregnancy and thus, 
the patient should be counseled about this and if there is any 
risk of pregnancy, it should be evaluated. Dosage ranges for 
spironolactone are 50–200 mg daily with most prescribers 
starting at 50–100 mg a day.
Systemic retinoids
Isotretinoin is the main systemic retinoid used in the treatment 
of acne, specifically severe nodulocystic acne. The mecha-
nisms of action of this drug include inhibition of sebaceous 
gland differentiation with a reduction in sebaceous gland size 
and sebum production, normalization of follicular epithelial 
desquamation, and inhibition of neutrophil chemotaxis. 
Recommended cumulative doses for the treatment of acne 
are 120–150 mg/kg with many practitioners using the higher 
end of this range. Isotretinoin has a variety of adverse effects 
associated with it. Almost every patient will have xerosis of 
the skin and chelitis. However, the side-effect of concern 
with this medication is teratogenicity, which is quite major. Clinical, Cosmetic and Investigational Dermatology 2009:2 109
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Up to 50% of fetuses exposed to this drug during the first 
trimester will have a major birth defect which includes major 
cardiovascular, craniofacial, ocular, auditory, central nervous 
system, and skeletal abnormalities.24 In the United States, 
a federally mandated program, iPledge has been instituted 
in an attempt to decrease the number of pregnancies while 
patients are on this medication. This program requires all 
patients to be registered with an iPledge number and also 
requires physicians, pharmacists and pharmacy distributors to 
also be registered if they are involved with the distribution of 
this drug. Long-term analysis has yet to show if this program 
decreases the number of pregnancies while on the drug.
Another concern about isotretinoin is whether this 
medication increases the risk of suicide and depression. 
A recent review of nine studies evaluating this concern 
was published.25 This systemic review found the rates of 
depression to be similar among users of isotretinoin and 
nonusers. The studies examined did not show a statisti-
cally significant increase in depression in isotretinoin 
users before or after treatment, and some showed that the 
patients had less severe depressive symptoms after treat-
ment. The authors of this review note that all these studies 
have limitations, but the data do not support a meaningful 
causative association. However, this association must be 
discussed with patients upon initiation of this drug and at 
each follow-up visit.
Superficial chemical peels
Chemical peeling of the skin has long been used in the 
treatment of acne. Most peeling for the treatment of acne is 
superficial. This discussion is focused on the treatment of 
acne rather than that of acne scarring. In general, most prac-
titioners use salicylic acid, glycolic acid, or trichloroacetic 
acid for the treatment of acne. Superficial chemical peeling 
can be done monthly, although some do the peels as often 
as every 2 weeks and some wait until every 6 weeks. Good 
patient education is necessary as patients should know what 
to expect with the peel. A good review of regimens used 
for patients in office settings is noted in a recent review.26 
In patients with ethnic skin, salicylic acid remains the peel-
ing agent of choice as the others have been associated with 
post-inflammatory pigment alteration. A recent comparison 
of alpha-hydroxy (30% glycolic acid) versus beta-hydroxy 
(30% salicylic acid) peels in a double-blind, randomized 
study found that both peels were equally effective in the 
treatment of acne.27 However, there were more reported 
adverse events after the initial treatment with the glycolic 
acid peel.
Laser and light devices
With technology progressing at a fast pace, it is not surprising 
that laser and light therapies would be of interest to those 
treating acne. Recently, the range of treatments for acne 
has included photodynamic therapy (PDT), light-emitting 
diode (LED) therapy and a combination of pneumatic energy 
and light for the treatment of acne. These therapies work 
best as adjuvant therapies when combined with traditional 
therapies.
PDT, which is the treatment of skin with aminolevulinic 
acid followed by photo activation of the compound, has 
been shown to help treat acne.28 Most patients are able to 
tolerate the procedure well, but in rare cases PDT has been 
associated with a painful pustular reaction while being used 
for the treatment of acne.
Red and blue light therapy is also used to treat acne, 
with the most recent advances being home-use products 
that allow the patient to deliver the light therapy at home 
by a handheld device. Recently, a report of a study using a 
handheld LED red and blue light device found that the lesion 
counts decreased throughout the 4-week treatment period and 
continued for up to 8 weeks post-therapy with the average 
reduction of 69% (p  0.001).29 Similarly, another study 
looking at acne in patients with type IV skin showed that the 
red and blue light combination treatment twice weekly for 
4 weeks resulted in improvements in noninflammatory and 
inflammatory lesions.30 As inflammatory lesions improved 
more, the authors felt this was a good treatment particularly 
for papulopustular acne.
A novel combination product called Isolaz™ (Aesthera, 
Pleasanton, CA, USA) which uses a vacuum along with a 
broad band light source, has been shown to be effective 
in the treatment of acne.31 This small study (11 patients) 
treated patients with the device at 3-week intervals and had 
significant decreases in both inflammatory and noninflam-
matory lesions. Most patients expressed satisfaction with 
this treatment.
Future treatment options
Probably the most interesting treatment on the horizon is 
vaccine therapy for acne. The vaccines are targeted against 
the P. acnes bacteria. As mentioned at the beginning of this 
article, acne is a multifactorial disease, and thereby targeting 
one area may not result in eradication of the condition. 
However, P. acnes is involved in diseases other than 
acne including infectious conditions such as endocarditis, 
endophthalmitis, osteomyelitis and post-surgery infections, 
and this has lead researchers to develop vaccines. A recent Clinical, Cosmetic and Investigational Dermatology 2009:2
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review highlights the latest work on the P. acnes vaccines 
and how they have shown good results and immunity, when 
used in mice challenged by P. acnes.32
In conclusion, practitioners should be aware of the 
traditional therapeutic choices for the treatment of acne, but 
should work to refine their knowledge about the different 
formulations of products available to them to prescribe. As 
to newer technologies, it is imperative that physicians are 
aware of these modalities and even if they are not actively 
using them, they should have a working knowledge of them 
to answer patient questions.
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